Genotype and Phenotype Landscape of 283 Japanese Patients with Tuberous Sclerosis Complex

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Oct 14

PMID 36232477

Authors

Sumihito Togi

Hiroki Ura

Hisayo Hatanaka

Yo Niida

Affiliations

Soon will be listed here.

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by multiple dysplastic organ lesions and neuropsychiatric symptoms, caused by loss of function mutations in either or . Genotype and phenotype analyses are conducted worldwide, but there have been few large-scale studies on Japanese patients, and there are still many unclear points. This study analyzed 283 Japanese patients with TSC (225 definite, 53 possible, and 5 genetic diagnoses). A total of 200 mutations (64 , 136 ) were identified, of which 17 were mosaic mutations, 11 were large intragenic deletions, and four were splicing abnormalities due to deep intronic mutations. Several lesions and symptoms differed in prevalence and severity between TSC1 and TSC2 patients and were generally more severe in TSC2 patients. Moreover, missense and in-frame mutations may attenuate skin and renal symptoms compared to other mutations. Genetic testing revealed that approximately 20% of parents of a proband had mild TSC, which could have been missed. The patient demographics presented in this study revealed a high frequency of TSC1 patients and a low prevalence of epilepsy compared to global statistics. More patients with mild neuropsychiatric phenotypes were diagnosed in Japan, seemingly due to a higher utilization of brain imaging, and suggesting the possibility that a significant amount of mild TSC patients may not be correctly diagnosed worldwide.

Citing Articles

A recurrent variant c.5126C>T in a Han-Chinese family with tuberous sclerosis complex.

Deng X, Wu S, Deng H, Yuan L Pak J Med Sci. 2025; 41(1):263-268.

PMID: 39867804 PMC: 11755278. DOI: 10.12669/pjms.41.1.10153.

Fetal and neonatal cardiac tumor diagnosed as Tuberous Sclerosis associated rhabdomyomas resulting from novel pathogenic missense variant detected in gene: A case report.

Kawasaki A, Tonoki H, Sasaki O, Matsushita Y, Watari M, Takahashi N Radiol Case Rep. 2025; 20(3):1526-1531.

PMID: 39811056 PMC: 11731587. DOI: 10.1016/j.radcr.2024.11.062.

Investigation of a novel PROS1 splicing variant in a patient with protein S deficiency.

Niida Y, Fujita W, Togi S, Ura H Hum Genome Var. 2024; 11(1):28.

PMID: 39060248 PMC: 11282053. DOI: 10.1038/s41439-024-00286-9.

Bleeding solitary SEGA in non-tuberous sclerosis complex adolescent: a case illustration and review of literature.

Yindeedej V, Rojnueangnit K, Chotsakulthong P, Thamwongskul C Childs Nerv Syst. 2024; 40(7):2199-2207.

PMID: 38578478 DOI: 10.1007/s00381-024-06382-z.

Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group.

Mekahli D, Muller R, Marlais M, Wlodkowski T, Haeberle S, de Argumedo M Nat Rev Nephrol. 2024; 20(6):402-420.

PMID: 38443710 DOI: 10.1038/s41581-024-00818-0.

References

Curatolo P, Bombardieri R, Jozwiak S . Tuberous sclerosis. Lancet. 2008; 372(9639):657-68. DOI: 10.1016/S0140-6736(08)61279-9. View

Shoji T, Konno S, Niida Y, Ogi T, Suzuki M, Shimizu K . Familial multifocal micronodular pneumocyte hyperplasia with a novel splicing mutation in TSC1: Three cases in one family. PLoS One. 2019; 14(2):e0212370. PMC: 6386448. DOI: 10.1371/journal.pone.0212370. View

Goyer I, Dahdah N, Major P . Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatr Neurol. 2015; 52(4):450-3. DOI: 10.1016/j.pediatrneurol.2015.01.004. View

Curatolo P, Moavero R, de Vries P . Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015; 14(7):733-45. DOI: 10.1016/S1474-4422(15)00069-1. View

Peral B, Ward C, Thompson P, Hughes J, Maheshwar M, Nellist M . Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet. 1994; 8(4):328-32. DOI: 10.1038/ng1294-328. View

Sasaki T, Uda T, Kuki I, Kunihiro N, Okazaki S, Niida Y . TSC2 somatic mosaic mutation, including extra-tumor tissue, may be the developmental cause of solitary subependymal giant cell astrocytoma. Childs Nerv Syst. 2021; 38(1):77-83. DOI: 10.1007/s00381-021-05399-y. View

Henske E, Jozwiak S, Kingswood J, Sampson J, Thiele E . Tuberous sclerosis complex. Nat Rev Dis Primers. 2016; 2:16035. DOI: 10.1038/nrdp.2016.35. View

. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993; 75(7):1305-15. DOI: 10.1016/0092-8674(93)90618-z. View

Richards C, Bale S, Bellissimo D, Das S, Grody W, Hegde M . ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008; 10(4):294-300. DOI: 10.1097/GIM.0b013e31816b5cae. View

10.

Kingswood J, dAugeres G, Belousova E, Ferreira J, Carter T, Castellana R . TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017; 12(1):2. PMC: 5217262. DOI: 10.1186/s13023-016-0553-5. View

11.

Togi S, Ura H, Niida Y . Application of Combined Long Amplicon Sequencing (CoLAS) for Genetic Analysis of Neurofibromatosis Type 1: A Pilot Study. Curr Issues Mol Biol. 2021; 43(2):782-801. PMC: 8929138. DOI: 10.3390/cimb43020057. View

12.

Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama I . Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients. PLoS One. 2013; 8(5):e63910. PMC: 3656843. DOI: 10.1371/journal.pone.0063910. View

13.

Carsillo T, Astrinidis A, Henske E . Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000; 97(11):6085-90. PMC: 18562. DOI: 10.1073/pnas.97.11.6085. View

14.

Rendtorff N, Bjerregaard B, Frodin M, Kjaergaard S, Hove H, Skovby F . Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations. Hum Mutat. 2005; 26(4):374-83. DOI: 10.1002/humu.20227. View

15.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

16.

Shoji T, Niida Y, Osawa T, Matsumoto R, Sakurai K, Suzuki M . Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex. Respir Med Case Rep. 2021; 34:101526. PMC: 8524238. DOI: 10.1016/j.rmcr.2021.101526. View

17.

Jozwiak J, Jozwiak S, Wlodarski P . Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol. 2008; 9(1):73-9. DOI: 10.1016/S1470-2045(07)70411-4. View

18.

Ismail N, Nik Abdul Malik N, Mohseni J, Rani A, Hayati F, Salmi A . Two novel gross deletions of TSC2 in Malaysian patients with tuberous sclerosis complex and TSC2/PKD1 contiguous deletion syndrome. Jpn J Clin Oncol. 2014; 44(5):506-11. DOI: 10.1093/jjco/hyu024. View

19.

Narayanan V . Tuberous sclerosis complex: genetics to pathogenesis. Pediatr Neurol. 2003; 29(5):404-9. DOI: 10.1016/j.pediatrneurol.2003.09.002. View

20.

Nakajima Y, Yamada K, Imamura K, Kobayashi K . Radiologist supply and workload: international comparison--Working Group of Japanese College of Radiology. Radiat Med. 2008; 26(8):455-65. DOI: 10.1007/s11604-008-0259-2. View